CME accreditation will be provided by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC). You will receive 1 hour of external CME credit for full attendance of the webinar, including completion of the pre-/post-CME test questions and evaluation.
Welcome and introductions
Luspatercept mechanism of action
- Reduction in anemia
- Erythropoiesis
NCT03194542 trial
- Study design
- Eligibility
- Primary endpoints
Key efficacy/safety findings
- Secondary endpoints
- Quality of life
- What's missing in this trial?
- Potential exploratory analysis
Luspatercept compared with other available therapies
- How will it add to the current clinical landscape?
Q&A Session
Evaluation/close
In compliance with EBAC guidelines, all speakers/chairpersons participating in this program have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.